Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease.

Dis Model Mech · 2014 · PMC4174530 · PMID 25085990

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

failed to reach statistical significanceP =0.058so close (0.05 < p ≤ 0.1)

5G revealed a trend for increased numbers of HuNu + cells in the LIF-nano-treated group compared with empty-nano controls, but this failed to reach statistical significance ( P =0.058; Fig. 5G , left panel).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.